We recently showed that male rats exhibit lower hypophagia and body weight loss compared to female rats following central leptin delivery, suggesting a role for oestradiol in leptin responsiveness. Accordingly, we delivered Ob (leptin) or GFP (control) gene into the brain of male rats that were simultaneously treated with oestradiol or vehicle. In a reciprocal approach, we compared oestradiol-deficient (OVX) with intact females (sham) that received leptin or control vector. Changes in food intake), body weight and body composition were examined. In males, oestradiol and leptin resulted in lower cumulative food intake (15%) and endpoint body weight (5%), although rats receiving dual treatment (oestradiol-leptin) ate 28% less and weighed 22% less than vehicle-control. Changes in food intake were unique to each treatment, with a rapid decrease in vehicle-leptin followed by gradual renormalisation. By contrast, hypophagia in oestradiol-control was of lower amplitude and sporadic. Leptin selectively targeted fat mass and endpoint abdominal fat mass was 65%-80% lower compared to their respective control groups. In females, both leptin groups had lower body weight (endpoint values 20% lower than control groups) with the highest extent in sham animals (endpoint value was 28% less in sham-leptin than in sham-control). OVX rats rapidly started regaining their lost body weight reminiscent of the pattern in males. Leptin rapidly and robustly reduced fat mass with endpoint values 30%-35% less than control treated animals. It appears that leptin and oestradiol decreased food intake and body weight via different mechanisms, with the pattern of oestradiol-leptin being reminiscent of that observed in females and the pattern of OVX-leptin reminiscent of that observed in males. Oestrogen status did not influence initial fat mass loss by leptin. It can be concluded that oestradiol modulates the long-term response to central leptin overexpression, although its actions on energy homeostasis are additive and independent of those of leptin.
K E Y W O R D S
oestradiol, female, leptin, male, weight loss Given the intertwined signalling pathways and physiological functions, a cross-talk network between these two hormones has been proposed. 3 Important evidence supports the theory that the functions of oestrogens and leptin are coupled. For example, leptin is essential for the secretion of gonadotrophin-releasing hormone from the pituitary and has an indirect effect on the secretion of oestrogens. 4 Reciprocally, oestrogens activate leptin secretion in adipose tissue and have a role in the expression of the long form of leptin receptor in the hypothalamus. 5, 6 Beyond those permissive effects, oestrogens have been shown to enhance central leptin signalling. Indeed, the brain of males is relatively less sensitive to the catabolic action of leptin than the brain of females. 7 However, feminisation of the male hormone milieu via administration of 17β-oestradiol enhances acute central leptin sensitivity. 8 Similarly, in females, oestrogen deficiency by ovariectomy (OVX) decreases central leptin sensitivity and hormone replacement therapy can re-establish the brain leptin response. 8 We recently reported that male rats are less responsive to long-term central leptin overexpression compared to female rats, as assessed by decreased food intake and delta body weight. Our findings suggest that the exacerbated response in females was at least partly a result of the higher level of oestradiol, although this interpretation remains speculative. The present studies further examine whether oestradiol enhances long-term leptin responses or whether the actions of oestrogen are independent of leptin. Accordingly, we conducted two additional experiments manipulating the hormonal milieu of rats that chronically overexpressed leptin in the brain. First, we attempted to recapitulate the female leptin response in males by daily administration of oestradiol in rats that were centrally delivered leptin gene. We then utilised a reciprocal approach in which we examined the response to central leptin overexpression in ovariectomised (oestradiol-deficient) compared to intact female rats.
| MATERIAL S AND ME THODS

| Animals and groups
For study 1, 3-month-old Sprague-Dawley rats (n = 32), were obtained from Taconic (Germantown, NY, USA). For study 2, (Fisher 344 × Brown Norway) F1 rats (n = 32) were obtained from the National Institute on Aging Colony at Charles River Laboratories (Wilmington, MA, USA). The hybrid rats are an ideal strain for these studies because they display a more stable body weight at adulthood. 9 However, these animals are bred at the National Institute on Aging with a limited distribution. It was not possible to obtain sufficient animals for both experiments, which explains the use of two different strains. Animals were housed individually under a 12:12 hour light/dark cycle. All rats were allowed at least 1 week to acclimate to their new environment and daily handling before beginning any experiment. During this initial acclimation period, in study 1, animals were given daily injections of saline to mimic stress induced during the experiment. We found in the past that acclimation to daily injections is useful for preventing stressinduced weight loss, which constitutes an important artefact in our experiments. All rats from these two experiments were fed a standard rodent chow (18% kcal from fat, no sucrose, 3.1 kcal g -1 ;
Envigo Teklad Global diet 2918; Envigo, Huntingdon, UK). Health status, body weight and food intake were monitored daily throughout the study. All experimental protocols were approved by the University of Florida's Animal Care and Use Committee, and in compliance with the eighth edition of Guide for the Care and
Use of Laboratory Animals. The day before the actual experiment started, rats were pseudo-randomised into two weight-matched groups that were centrally delivered a vector to overexpress either a green fluorescent protein (control), or leptin. For study 1, animals from each of these two groups were then assigned to received daily injections of either oestradiol (25 μg kg -1 diluted in sesame oil; s.c.; 0.5 mL kg -1 ) or vehicle (sesame oil; 0.5 mL kg -1 ).
We selected daily rather than cyclic injection because oestradiol is quickly metabolised. Oil was chosen over ethanol to promote slower but more constant release of oestradiol. 10 Therefore, there were four male groups: vehicle-control, vehicle-leptin, oestradiol-control and oestradiol-leptin. All treatments, daily injections and gene delivery started on experimental day 0.
For study 2, half of the animals from control and leptin group were assigned to either OVX or sham operation (sham). There were also four groups of females: OVX-control, OVX-leptin, sham-control and sham-leptin. In the present study, sham groups are often referred as groups with "higher oestrogen levels" and OVX animals are referred to as groups with "lower oestrogen levels". In the figures, data for OVX groups are presented on the left side for clarity.
The typical presentation order (sham-control on the left side) was reversed to better align with the experimental conditions; columns on the left represent groups of animals with lower oestrogen levels and columns on the right comprise groups of animals with high oestrogen levels.
| Surgeries
For both studies, on day 0, rats were anaesthetised with isoflurane (2%-3%) and administered the analgesics buprenorphine 
| Tissue collection, harvesting and preparation
On day 25 (study 1) or day 28 (study 2), rats were euthanised between 10 am and 12 pm by exsanguination (intra-cardiac blood collection) under anaesthesia (isoflurane; 5%). The hypothalamus was dissected from the whole brain by a medial incision to the piriform lobes, caudal to the optic chiasm and anterior to the cerebral crus to a depth of 2.5 mm and immediately snap frozen in liquid nitrogen. Then, the samples were stored at −80°C until analyses were performed. Four abdominal fat depots were collected and weighed: mesenteric, perirenal, epididymal/parametrial and retroperitoneal.
| Reverse transcription polymerase chain reaction
Total RNA was isolated from the hypothalamus using TRI reagent (Sigma-Aldrich, St Louis, MO, USA). Total RNA (2 μg) was reverse-transcribed into complementary DNA using high-capacity complementary DNA reverse transcription kits (Applied Biosystems, Waltham, MA, USA). Leptin expression was determined with SYBR Green Supermix using primer sets designed to amplify leptin transgene from the vector (forward 5′-GGCAACGTGCTGGTTATTGT-3′ and 5′-ATAT CCATCACACTGGCGGC-3′). Gapdh (forward 5′-TCTCTGCTCCTCCC TGTTCT-3′ and reverse 5′-TACGGCCAAATCCGTTCACA-3′) was used to normalise. The iQ detection system (Bio-Rad, Hercules, CA, USA) was used to detect the amplification threshold and programmed with an initial step of 3 minutes at 95°C, followed by forty cycles for 5 seconds at 95°C and 15 seconds at 60°C. All reactions were run in duplicate and the average of threshold cycle (C t ) was used in our calculations. The relative quantification of the target genes was calculated with the ΔΔC t method. The C t values of the target genes were normalised (ΔC t = C t target −C t GAPDH ) and compared with a calibrator (ΔΔC t = ΔC t Sample −ΔC t Calibrator ). Relative expression was calculated using software provided with the iQ detection system (Bio-Rad).
| Western analysis
The hypothalami were sonicated in 270-300 μL of homogenisa- 
| Serum leptin, oestradiol and testosterone
Enzyme immunoassays were used to measure serum hormone levels. Serum was separated from blood drawn in fed animals.
Oestradiol was not administered on the day of death. Therefore, serum analyses were performed approximately 24 hours after the last oestradiol injection. Leptin kit used (Millipore, Waltham, MA, USA) has a sensitivity allowing the detection of levels between 0.04 and 40 ng mL -1 with an intra-assay variability of approximately 2%.
Oestradiol kit can detect levels in the range 1.4-200 pg mL -1 with intra-assay variability of <9% (ALPCO, Salem, NH, USA). The testosterone kit has a sensitivity allowing the detection of serum levels in the range 0.1-25 ng mL -1 with an intra-assay variability of <9% (ALPCO).
| Statistical analysis
The results are expressed as the mean ± SE. For endpoint analyses, differences between means were tested for statistical significance (P < 0.05) using a regular two-way ANOVA with leptin and oestrogen status (oestradiol treatment for males and OVX for females) as main factors. Tukey's multiple comparison tests were applied in the event of a significant interaction (P < 0.05). For longitudinal analyses, we employed repeated measures (mixed model) ANOVA using time and groups as main factors and performed a Tukey's post-hoc test in the case of significance.
| RE SULTS
Leptin transgene was delivered in a way that favoured leptin receptor binding throughout the brain. We utilised rAAV serotype one to readily infect cells adjacent to the third ventricle and because this serotype is less specific to neurones. Our leptin vector construct contains a secretory sequence directing the transgene product to be discharged into the third ventricle to activate leptin receptors throughout the brain. Transgene expression was determined by a quantitative polymerase chain reaction using a sense primer against the vector that is not present in leptin gene and an antisense primer against native leptin gene. We confirmed the presence of leptin transgene in the hypothalamus of animals from study 1 and 2. In study 1, leptin transgene expression relative to beta-actin in leptin treated animals was 3800-fold that of control animals (P < 0.001).
Similarly, in study 2, leptin transgene expression relative to betaactin in leptin treated animals was 5800-fold that of control animals (P < 0.001). Data were reported in previous studies. anorexigenic molecule known to stimulate a subset of neurones that are also activated by leptin: the pro-opiomelanocortin neurones. 2 It was expected that male rats with low (normal) oestrogen levels would eat significantly more than those with high oestrogen levels.
Indeed, the oestradiol-vehicle group had diminished food intake compared to vehicle-control; however, the pattern was distinctly different from that induced by leptin. The decrease in food intake was of lower amplitude and sporadic ( Figure 1A ). Moreover, separate t-test analyses revealed that, early in the study, food intake was lower in vehicle-leptin than in oestradiol-control (cumulative food intake days 5-10, P < 0.01) ( Figure 1A ); in contrast, near the end of the study, the oestradiol-control rats consumed less food than vehicle-leptin rats (cumulative food intake days 20-25, P < 0.05) ( Figure 1A ), demonstrating that these two treatments have distinct and independent anorexigenic effects. However, there was no difference in overall cumulative food consumption between these two groups (vehicle-leptin vs oestradiol-control: P > 0.05) ( Figure 1B ).
The combined effect of high oestrogen and leptin was more than that each effect alone (oestradiol-leptin vs oestradiol-control/vehicle-leptin: P < 0.001) ( Figure 1A ) but did not exceed the summation of the effect of each treatment alone; hence, the effects were not potentiating but simply additive.
F I G U R E 1 Daily and cumulative food intake and body weight in study 1. A, Daily food intake was reduced by oestradiol and/or leptin. There was a significant main effect of leptin from day 5 to day 14( † vehicle-control vs vehicle leptin and oestradiol-control vs oestradiol-leptin: P < 0.05). The effect of oestradiol was sporadic but could be observed throughout the duration of the study (*vehiclecontrol vs oestradiol-control and vehicle-leptin vs oestradiol-leptin: P < 0.05). There were significant differences between the two single-treatment groups from day 2 to day 9: vehicle-leptin vs oestradiol-control: P < 0.05 (not labelled). B, Cumulative food intake followed the same pattern as daily food intake with two significant main effects: leptin and oestradiol ( † † † vehicle-control vs vehicle leptin, † † † oestradiol-control vs oestradiol-leptin, ***vehicle-control vs oestradiol-control, ***vehicle-leptin vs oestradiol-leptin: P < 0.001). There was no difference between the two single-treatment groups: vehicle-leptin vs oestradiol-control: P > 0.05. C, Body weights were reduced by leptin and/or oestradiol. At the initiation of the study, body weights of the four groups were similar (vehiclecontrol: 407.5 ± 6.2; vehicle-leptin: 410.8 ± 5.6; oestradiol-control: 409.2 ± 5.4; oestradiol-leptin: 403.4 ± 7.6). Body weight patterns followed changes in food intake with significant differences between leptin and control groups, as well as between oestradiol and vehicle groups (vehicle-control vs vehicle-leptin, oestradiolcontrol vs oestradiol-leptin, vehicle-control vs oestradiol-control and vehicle-leptin vs oestradiol-leptin: P < 0.05). *Oestradiol effect (days 11-25; P < 0.05); † leptin effect (days 9-25; P < 0.05). Values are the mean ± SE 
| Oestradiol and leptin have distinct effects on body composition as reflected by significant differences in lean to fat mass ratio between the two single treatment groups
Leptin vector also had significant impact on body weight and body composition. At the initiation of the study, body weights of the four male groups were similar (average of 410 ± 2.3 g). Leptin
induced weight loss (−5% of initial body weight) and diminished body weight gain, as indicated by differences in body weight.
Endpoint body weight was 13% less in leptin-treated males compared to their corresponding control groups (vehicle-leptin vs vehicle-control and oestradiol-leptin vs oestradiol-control: Figure 1C) . Similarly, fat mass was diminished by leptin from day 7 until the end of the study and endpoint fat mass was 22%-25% lower in leptin groups than in control groups (vehicle-leptin vs vehicle-control and oestradiol-leptin vs oestradiolcontrol: P < 0.001) (Figure 2A ). The overall effect of leptin on fat mass was reflected by the lower endpoint abdominal fat mass (retroperitoneal, perirenal, epididymal and mesenteric fat pad mass), which was 68%-82% lower in leptin groups than in control groups and was also reflected by the 50%-70% lower serum leptin levels (vehicle-leptin vs vehicle-control and oestradiol-leptin vs oestradiol-control: P < 0.001) ( Figure 3A ,B). Starting on day 14, lean mass was significantly lower in leptin groups than in respective control groups and was 15%-17% lower at endpoint (vehicle-leptin vs vehicle-control and oestradiol-leptin vs oestradiol-control: Figure 2B ). Oestradiol is also known to have significant effect on body weight through its anorexigenic potential and activation of the sympathetic nervous system. As expected, oestradiol treatment decreased body weight or prevented weight gain (vehicle-control vs oestradiol-control and vehicle-leptin vs oestradiol-leptin: P < 0.001) ( Figure 1C ). Oestradiol treatment alone did not reduce initial fat mass beyond 7 days of treatment but prevented fat mass gain or regain observed in vehicle treated groups.
Endpoint fat mass was 13%-18% less in oestradiol treated than in vehicle treated (vehicle-control vs oestradiol-control and vehicleleptin vs oestradiol-leptin: P < 0.001) (Figure 2A ).
Male rats that received dual treatment (oestradiol-leptin) lost significantly more body weight than all other groups (P < 0.001) ( Figure 1C ). On the other hand, fat mass loss in the groups with high oestrogen and leptin was mostly a result of leptin, at least in the first 3 weeks. From day 0 to day 21, there was no additional fat mass loss in the leptin group that received oestradiol than in the group that did not (oestradiol-leptin vs vehicle-leptin: P > 0.05) (Figure 2A ). The presence of both anorexigenic conditions resulted in a more sustained fat mass loss. At day 25, oestradiol-leptin males had maintained most of their fat mass loss while vehicle-leptin males essentially regained it (vehicle-leptin vs oestradiol-leptin: (Figure 2A ). This was also reflected by the 50% lower endpoint abdominal fat mass in the oestradiol-leptin, compared to vehicle-leptin (P < 0.001) (Figure 2A ). Although oestradiol-leptin group had significantly lower fat mass than vehicle-leptin, there was no difference in serum leptin between these two groups (oestradiol-leptin vs vehicle-leptin: P > 0.05) ( Figure 2B ). The lost lean body mass appeared to be mainly a result of oestradiol. At the end of the study, lean body mass was 12%-25% less than all other groups (oestradiol-leptin vs oestradiol-control/vehicleleptin/vehicle-control: P < 0.001) ( Figure 2B ). As a result of the time between the last oestradiol injection and blood draw, we did not observe a significant increase in serum oestradiol (vehicle 2.72 ± 0.87 pg/mL vs oestradiol 6.78 ± 4.38 pg/mL; P > 0.05). It F I G U R E 2 Absolute fat mass and lean mass in study 1. A, There was a significant loss in fat mass by leptin and, starting at day 7, leptin-treated groups showed a significantly lower fat mass than the corresponding control groups (vehicle-leptin vs vehicle-control and oestradiol-leptin vs oestradiol-control: P < 0.001). Oestradiol treatment decreased fat mass toward the end of the experiment and absolute fat mass was significantly lower in oestradiol treated groups at day 25 (oestradiol-control vs vehicle-control and oestradiol-leptin vs vehicle-leptin: P < 0.001. Noteworthy, there was a significant difference in absolute fat mass between the two single-treatment groups at days 7, 14 and 21 (oestradiol-control vs vehicle-leptin: P < 0.01). Absolute values at days 0, 7, 14, and 25 are shown. ***Oestradiol effect (P < 0.001), *(P < 0.05); † † † leptin effect (P < 0.001). B, Lean mass was diminished by oestradiol at day 7 (oestradiol-control vs vehicle-control: P < 0.001). At that time point, lean mass was not changed by leptin. The oestradiol effect size on lean mass was increasingly higher over time. Starting at day 21, there was a significant effect of leptin (vehicle-leptin vs vehiclecontrol and oestradiol-leptin vs oestradiol-control: P < 0.05). At day 25 only, there was a slight but significant difference in delta lean body mass between the two single-treatment groups (oestradiolcontrol vs vehicle-leptin: P < 0.05). appears that delay in the blood draw was sufficient time to clear the exogenous oestradiol from the blood stream. The other potential reasons for this lack of effect is the choice of vehicle (sesame oil), which minimises the release kinetics of oestradiol and lowers the peak amplitude compared to ethanol. 10 Regardless, male rats in oestradiol groups showed significantly lower serum testosterone levels (vehicle-control vs oestradiol-control and vehicle-leptin vs oestradiol-leptin: P < 0.001) ( Figure 3C ). This outcome is expected
given that oestradiol provides strong feedback inhibition on the luteinising hormone/follicle-stimulating hormone axis, resulting in suppression of testosterone secretion.
17,18
| Oestradiol increases the proportion of activated STAT3 but not the absolute amount of P-STAT3
Phosphorylation of STAT3 (P-STAT3) was examined in the hypothalamus at death. No exogenous leptin was administered, and so the detected P-STAT3 was a result of centrally overexpressed leptin. As expected, the P-STAT3:STAT3 ratio was greater in both leptin groups compared to the respective controls (P < 0.001) ( Figure 4A ).
Oestradiol treated animal also exhibited a significantly higher P-
STAT3:STAT3 ratio (vehicle-control vs oestradiol-control and vehi-
cle-leptin vs oestradiol-leptin: P < 0.01) ( Figure 4A ) with the highest P-STAT3 relative abundance in the leptin-oestradiol group, suggesting that oestradiol may alter leptin signalling. However, when normalised to beta-actin, P-STAT3 was not affected by oestradiol, although P-STAT3 was higher in both leptin groups compared to the control groups (P < 0.001) ( Figure 4B ). These differential results are apparently the result of a relative increase in total STAT3 with leptin treatment and a decrease in total STAT3 with oestradiol treatment when normalised to beta-actin (P < 0.01) ( Figure 4C ). This indicates a proportional increase in P-STAT3 but not an absolute increase in P-STAT3 with oestradiol treatment.
| Study 2: Ovariectomised vs ovary intact females
| leptin induced anorexia, regardless of their oestrogen status
In study 1, leptin induced anorexia in all male rats, regardless of whether they were vehicle-treated (ie, low oestrogen levels) or oestradiol-treated. In study 2, at days 0-7 post central vector delivery, animals treated with AAV-leptin underwent the typical initial hypophagic phase and food consumption was diminished in both leptin groups, regardless of whether oestrogen levels were low (OVX) or normal (sham). Indeed, both leptin groups ate significantly less food than control groups (OVX-leptin vs OVX-control and sham-leptin vs sham-control: P < 0.001) ( Figure 5A ). Although the initial hypophagia in response to leptin faded over time, leptin-treated animals consumed significantly less food after the expected hypophagic phase (OVX-leptin vs OVX-control and sham-leptin vs sham-control:
Figure 5B). Similar to oestradiol treatment in males, the presence of endogenous female hormones in sham lowered food intake, although this effect appeared to be distinct from leptin. In this sense, during the leptin-hypophagic response (days 0-7), OVX did not significantly affect food intake (OVX-leptin vs sham-leptin and OVX-control vs sham-control: P > 0.05) ( Figure 5A ). Beyond the initial leptin hypophagic phase (days 8-28), OVX animals consumed more food than sham animals (OVX-control vs sham-control and OVX-leptin vs sham-leptin: P < 0.001) ( Figure 5A,B) . Similar to males, animals with dual anorexigenic condition (sham [gonadally-intact/
higher oestrogen] + leptin) ate significantly less food than groups with single anorexigenic condition (sham-leptin vs OVX-leptin or F I G U R E 3 Endpoint fat mass and serum leptin levels in study 1. A, Intra-abdominal fat mass (sum of epididymal, retroperitoneal, perirenal and mesenteric fat depot weights) was decreased by leptin (P < 0.001) and oestradiol (P < 0.05). B, Serum leptin levels were reduced in oestradiol-control compared to vehiclecontrol (P < 0.05), although there was no difference between oestradiol-leptin and vehicle-leptin (P > 0.05). The effect of leptin was observed in both vehicle and oestradiol-vehicle treated males (vehicle-leptin vs vehicle-control and oestradiol-leptin vs oestradiol-control: P < 0.001). Values are the mean ± SE. C, Serum testosterone was significantly lower in both oestradiol groups (P < 0.001). ***Oestradiol effect (P < 0.001), *(P < 0. sham-control; P < 0.001) ( Figure 5B ). However, there was no difference in cumulative (days 0-28) food consumption between the two groups with single anorexigenic condition (sham-control vs OVXleptin: P > 0.05) (data not shown). As observed in males, the combined effect of higher oestrogen and leptin (sham-leptin) was greater than that of each effect alone (sham-control or OVX-leptin) but were simply additive.
| OVX did not prevent females from losing body weight in response to leptin
As anticipated, leptin-treated rats lost a significant amount of body weight (sham-control vs sham-leptin and OVX-control vs OVX-leptin: P < 0.001) ( Figure 5C ). As observed in males, high oestrogen status resulted in higher body weight loss (sham-control vs OVX-control and sham-leptin vs OVX-leptin: P < 0.001) ( Figure 5C ).
However, despite consuming the same amount of food, the OVXleptin group lost significantly more body weight than sham-control and endpoint body weight was 8% less in OVX-leptin and shamcontrol (P < 0.001) ( Figure 5C ). Fat mass was drastically reduced in both leptin groups and endpoint fat mass measured by TD-NMR was 33%-35% lower than in control groups (sham-control vs shamleptin and OVX-control vs OVX-leptin: P < 0.001) ( Figure 6A ). Fat mass was unchanged by oestrogen status at day 14. At day 28, fat mass was 13% higher in OVX-control compared to sham-control (P < 0.05) ( Figure 6A) ; however, this difference was not reflected F I G U R E 4 Hypothalamic phospho-STAT3 (P-STAT3) levels in study 1. A, When normalised to total STAT3, relative expression of P-STAT3 was significantly increased in leptin groups compared to control groups (P < 0.001) and in oestradiol compared to vehicle groups (P < 0.01). Values represent densitometry of P-STAT3 analysis divided by densitometry obtained from total STAT3 analysis. B, When normalised to betaactin, relative expression of P-STAT3 was significantly increased in leptin groups compared to control groups (P < 0.001); however, there was no difference between oestradiol and vehicle treated groups. Values represent densitometry of P-STAT3 analysis divided by densitometry obtained from beta-actin analysis. C, Total STAT3 protein levels were normalised to beta-actin. Leptin treated groups exhibited significantly higher STAT3 levels compared to control groups (P < 0.01). By contrast, oestradiol groups displayed significantly less STAT3 than vehicle treated groups (P < 0.01). Values are the mean ± SE. **Oestradiol effect (P < 0.01); † † † leptin effect (P < 0.001). there was no effect of OVX. OVX resulted in dramatically lower uterus weight (P < 0.001), confirming the success of the surgical procedure ( Figure 7C ).
F I G U R E 5
Food intake (FI) during (days 0-7) or after (days 8-28) the initial hypophagic response to leptin, and changes in body weight in study 2. A, During the expected initial hypophagic phase, there was a main effect of leptin (sham-control vs sham-leptin and oestradioldeficient [OVX]-control vs OVX-leptin, P < 0.001); however, there was no main effect of OVX: P > 0.05. B, Cumulative food intake after the expected initial hypophagic phase induced by leptin, between days 8 and 28. Although the initial hypophagia in response to leptin faded, there was still a main leptin effect (sham-control vs shamleptin and OVX-control vs OVX-leptin, P < 0.001) and the OVX effect also surfaced (sham-control vs OVX-control and sham-leptin vs OVX-leptin: P < 0.001). There was no difference between OVX-leptin and sham-control: P > 0.05. C, Body weight was significantly changed by leptin and oestrogen status (sham-control vs sham-leptin, OVXcontrol vs OVX-leptin, sham-control vs OVX-control and sham-leptin vs OVX-leptin: P < 0.001). Despite consuming the same amount of food, the OVX-leptin group lost significantly more body weight than sham-control: P < 0.001. Values represent the individual change (%) in initial values (body weight) recorded on the day of vector delivery. ***OVX effect (P < 0.001); *(P < 0.05); † † † leptin effect (P < 0.001), † (P < 0.05). Vehicle-control (n = 6), vehicle-leptin (n = 7), oestradiolcontrol (n = 7) and oestradiol-leptin (n = 9) F I G U R E 6 Absolute fat mass and lean mass in study 2. A, Fat mass was drastically decreased by leptin and both leptin-treated groups lost about 30% of their initial fat mass 14 days after vector delivery (sham-control vs sham-leptin and oestradiol-deficient [OVX]-control vs OVX-leptin: P < 0.001) and the magnitude of this effect was maintained until the end of the experiment (P < 0.001). There was no effect of oestrogen status on fat mass at day 14. However, at day 28, sham-control animals had slightly lower fat mass gain than OVX-control rats (P < 0.05). 
| D ISCUSS I ON
Fundamental aspects of metabolic homeostasis are sex-biased and have important implications for the treatment of obesity-related health conditions. For example, a combination of glucose lowering agents has greater therapeutic potential in females than males. 19 Another concrete example is the sexual dimorphism in the anorexigenic response to methylphenidate, a drug that increases dopamine in the brain. There is a superior satiation effect in males compared to females. 20 Given that male and female feeding and metabolic circuitries are wired differently, 21 further understanding sexual dimorphisms in energy homeostasis may help design better therapeutic interventions to combat obesity in both sexes.
The adipocyte-derived hormone leptin may constitute a primary source of sex differences in energy homeostasis. Leptin regulates both aspect of the energy balance, intake and expenditure.
Cumulative evidence indicates that leptin acts more effectively in females than in males. Indeed, acute central leptin treatment induces stronger anorexia in females than in males. 22 In 23 Therefore, it is not surprising that administration of the MC4R antagonist HS014 has a stronger obesogenic effect in males than in females. 24 The orexigenic gene Npy, suppressed by leptin, is expressed at a higher level in males than in female rats and testosterone increases the concentration of neuropeptide Y (NPY) in the arcuate nucleus, potentially constituting an important underlying mechanism for larger appetite in males. 25 Expression levels of two orexigenic molecules controlled by leptin, NPY and agouti-related peptide are inversely correlated with oestrogen levels throughout the oestrous cycle. 26 Therefore, oestradiol levels appear to play an important role in the regulation of appetite.
| In males, oestradiol and leptin have separate but cumulative effects on food intake and body weight
We hypothesised that the enhanced response to central leptin gene delivery in female rats was a result of the hormonal milieu; more specifically, to the higher level of oestradiol. To further explore this possibility, we compared vehicle-treated vs oestradiol-treated males that were centrally delivered via AAV to overexpress either leptin or a control gene. As expected, oestradiol-leptin male rats had the greatest and most sustained body weight loss, reminiscent of the female response to chronic overexpression of leptin in the brain. with a rapid decrease in vehicle-leptin followed by gradual renormalisation typical of leptin-induced leptin resistance in male rats. 28 By contrast, decrease in food intake in the oestradiol-control group was of lower amplitude but sustained over the 25 days. This finding is in agreement with a previous report in which chronic but not acute oestradiol treatment suppressed feeding in ovariectomised
sheep. 29 The long-term suppression of food intake by oestradiol may be explained by near-complete suppression of testosterone since it is a potent orexigenic hormone. 30 Testosterone induces the expression of orexigenic NPY and represses the expression of anorexigenic pro-opiomelanocortin in the arcuate nucleus. 30 It is unclear whether oestradiol treatment influenced leptin signalling in the present study. On the one hand, oestradiol treated groups showed a higher proportion of activated STAT3 (P-STAT3: STAT3 ratio) compared to vehicle treated, suggesting that leptin signalling was enhanced.
This interpretation is supported by previous reports indicating that oestradiol increases phosphorylation of STAT3. 31, 32 However, when P-STAT3 levels were determined relative to beta-actin expression,
there was no effect of oestradiol, suggesting that oestradiol did not affect leptin signalling. Assessment of leptin STAT3 phosphorylation signalling following an acute leptin injection in oestradiol treated male rats may help resolve this issue.
| In males, leptin but not oestradiol appears to reduce body weight primarily through fat mass loss
Other evidence supporting the conclusions that oestradiol and leptin act independently were the fat mass changes over time. Within the first 14 days post vector delivery, oestradiol alone minimally reduced fat mass loss, whereas leptin robustly depleted fat stores, independent of oestrogen status. The effect of oestradiol on fat mass surfaced toward the end of the study when it could be observed oestradiol treatment clearly mitigated fat mass gain or regain in control and leptin groups, respectively. Treating the males with oestradiol did enhance and prolong leptin-mediated fat mass loss but did not completely recapitulate the female phenotype. In our previous study, females receiving the same treatment maintained a fat mass loss of 22% of their initial fat mass, 14 whereas males in the present study essentially regained their lost fat mass. Environment variables could have contributed to the inter-experiment differences; however, given the similarities of the animals (age, weight, and strain) and treatment (same vector batch, dose and duration of the experiment), it is likely that other anabolic factors in males and/or other catabolic factors in females account for the differences. For example, male animals in the present study exhibited a near-complete suppression of circulating testosterone in response to oestradiol administration, which was expected given that oestradiol produces potent feedback inhibition on the luteinising hormone/follicle-stimulating hormone axis and suppresses testosterone secretion in males. 17, 18 This effect may, at least partially, explain the adiposity differences among studies because testosterone and oestradiol collectively lower fat mass in males and inhibit a variety of lipogenic-related genes in visceral fat. 33 On the other hand, the effect of each treatment on lean mass was less obvious. Both single treatment groups maintained a steady level of lean mass throughout the study, whereas both oestradiol treated groups ended the experiment with slightly lower absolute lean mass than baseline. The lower lean mass in oestradiol treated groups may be explained by muscle wasting. Indeed, gastrocnemius muscle mass was 10% lower in oestradiol groups than in vehicle treated groups (P < 0.01; data not shown) most likely as a result of low testosterone levels. In agreement with this hypothesis, testosterone deficiency by gonadectomy reduces muscle mass. OVX. 35 Similar to males, the effect of oestrogen was additive to the effect of leptin; therefore, sham-leptin females lost the highest amount of weight. As observed in the male experiment, there was a rapid and robust decrease in daily food intake by leptin early in the study (days 0-7). During that same period, oestrogen status did not affect appetite. However, beyond leptin hypophagic phase (days 8-28), higher levels of female gonadal hormones were associated with lower food intake, supporting the conclusions drawn from the male study that leptin and oestradiol have distinct effects on food intake. Leptin and oestrogen status also appeared to differentially affect body weight. As expected, OVX animals did not lose body weight to the same extent as sham animals in response to leptin, reminiscent of the pattern observed in males. However, sham-leptin animals lost more body weight than OVX-leptin animals, although differences in body weight were a result of lean mass loss, not fat mass loss. These data support the interpretation that female hormones contribute to enhanced body weight loss independently of leptin.
| In females, leptin but not oestradiol appears to reduce body mass primarily through fat mass loss
Among the most striking observations of the present study, oestradiol and leptin were seen to independently decrease body weight by targeting different body compartments. In this regard, the female study is consistent with the male study and indicates that leptin primarily targets fat mass. In both studies, oestrogen status did not affect the initial fat mass response. Differences in leptin-induced body weight loss in OVX versus sham were not a result of fat mass. Instead, the endpoint body weight of these two groups differed because of lean mass. Consistent with males with low oestrogen levels, OVX animals tended to preserve their lean mass better than did sham animals. It can be explained at least partly by differences in cumulative food intake. OVX is an extensively used approach to evaluate the contribution of female hormones in biological processes, although it has some limitations such as the sudden depletion of oestrogen levels. Such a rapid change certainly triggered several physiological compensations that are difficult to account for or duplicate in control rats. Nevertheless, the present study does not support a major role of oestrogen in the female leptin response and it appears that oestradiol and leptin have independent effect in the regulation of energy homeostasis.
Our findings indicate that oestradiol and leptin have independent modes of actions to maintain energy homeostasis. Feminising 
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